Boston Scientific Corporation $BSX Stock: Bank Pictet & Cie Europe AG Decreases Holdings

Bank Pictet & Cie Europe AG trimmed its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 72.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 194,277 shares of the medical equipment provider’s stock after selling 523,696 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Boston Scientific were worth $8,480,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of BSX. Net Worth Advisory Group acquired a new position in shares of Boston Scientific during the 3rd quarter worth approximately $361,000. CWA Asset Management Group LLC raised its position in shares of Boston Scientific by 4.7% in the third quarter. CWA Asset Management Group LLC now owns 6,530 shares of the medical equipment provider’s stock valued at $285,000 after buying an additional 295 shares in the last quarter. Jackson Square Capital LLC bought a new stake in shares of Boston Scientific in the third quarter valued at approximately $2,408,000. Kaufman Rossin Wealth LLC bought a new stake in shares of Boston Scientific in the third quarter valued at approximately $429,000. Finally, Generali Investments Management Co LLC grew its position in Boston Scientific by 18.6% during the third quarter. Generali Investments Management Co LLC now owns 56,964 shares of the medical equipment provider’s stock worth $2,486,000 after buying an additional 8,924 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney purchased 186,240 shares of the stock in a transaction dated Monday, August 3rd. The stock was bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the acquisition, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David C. Habiger purchased 2,100 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director directly owned 17,160 shares in the company, valued at $816,644.40. The trade was a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 194,522 shares of company stock worth $9,385,210 over the last quarter. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

NYSE BSX traded up $0.15 during trading on Tuesday, hitting $45.20. 7,378,052 shares of the company’s stock were exchanged, compared to its average volume of 18,504,900. The company has a market cap of $65.51 billion, a PE ratio of 18.31, a P/E/G ratio of 1.07 and a beta of 0.58. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a fifty-two week low of $41.38 and a fifty-two week high of $105.65. The stock’s 50 day moving average price is $45.95 and its two-hundred day moving average price is $49.54.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period last year, the company posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts expect that Boston Scientific Corporation will post 3.24 EPS for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on BSX. Jefferies Financial Group dropped their price objective on Boston Scientific from $67.00 to $60.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Robert W. Baird set a $56.00 target price on Boston Scientific in a report on Thursday, July 30th. Evercore decreased their price target on Boston Scientific from $65.00 to $52.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 7th. Citigroup dropped their price target on Boston Scientific from $50.00 to $48.00 and set a “neutral” rating for the company in a research note on Monday, October 5th. Finally, UBS Group cut their price objective on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $68.23.

Boston Scientific Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.